Novartis licenses nanotech platform in search of diabetes therapy

Privately-held Canadian firm Parvus Therapeutics has entered into a license and collaboration agreement with Swiss pharma giant Novartis (NOVN: VX) for its lead therapy candidate in diabetes.

The company is attempting to create disease-modifying nanomedicines that will halt or reverse autoimmune diseases, without causing general immune suppression.

Parvis has developed a technology to create ‘Navacims,’ which the company calls “a novel pharmacological class of therapeutic comprised of nanoparticles that alter the behavior of disease-causing T lymphocytes.”